We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The rationale and toxicity of combined cranial radiotherapy and immune checkpoint inhibitors in non‐small cell lung cancer.
- Authors
Chen, Yi; Zhuang, Hongqing; Wang, Junjie
- Abstract
Cranial radiation therapy (CRT) remains to be the foundation stone of the management of brain metastases in non‐small cell lung cancer (NSCLC). Nevertheless, the care of NSCLC, recently, has been remarkably reshaped by the immune checkpoint inhibitors (ICIs), such as programmed death protein‐1 and programmed death ligand‐1 inhibitors, which even showed some efficacy in brain metastases. Furthermore, radiotherapy, traditionally regarded as a therapy via localized cytotoxicity, recently was reported to trigger a systemic immune response, thus probably enhancing the antitumor effect of ICIs. Preliminary datasets confirmed that the combination of these two therapies seemed superior to either monotherapy in NSCLC patients with brain metastases with improved efficacy and comparable toxicity. In this review, we started with discussing the rationale for the combination of CRT and ICIs, then outlined the clinical evidence supporting the high safety of this combined therapy, and finally made a preliminary conclusion on the safety of the combination of CRT and ICIs.
- Subjects
NON-small-cell lung carcinoma; IMMUNE checkpoint inhibitors; PEMBROLIZUMAB; RADIOTHERAPY
- Publication
Asia Pacific Journal of Clinical Oncology, 2022, Vol 18, Issue 3, p165
- ISSN
1743-7555
- Publication type
Article
- DOI
10.1111/ajco.13327